Onyx Pharmaceuticals Inc. (ONXX): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Onyx Pharmaceuticals ( ONXX) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.4%. By the end of trading, Onyx Pharmaceuticals rose $2.84 (2.2%) to $129.25 on heavy volume. Throughout the day, 3,520,443 shares of Onyx Pharmaceuticals exchanged hands as compared to its average daily volume of 1,688,500 shares. The stock ranged in a price between $125.44-$132.31 after having opened the day at $125.44 as compared to the previous trading day's close of $126.41. Other companies within the Health Care sector that increased today were: Biocryst Pharmaceuticals ( BCRX), up 51.2%, TrovaGene ( TROV), up 21.3%, Chelsea Therapeutics International ( CHTP), up 16.0% and PetMed Express ( PETS), up 13.6%.

Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally. Onyx Pharmaceuticals has a market cap of $9.4 billion and is part of the drugs industry. Shares are up 70.2% year to date as of the close of trading on Friday. Currently there are 11 analysts that rate Onyx Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Onyx Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and weak operating cash flow.

On the negative front, Mast Therapeutics ( MSTX), down 34.6%, Oxygen Biotherapeutics ( OXBT), down 23.9%, CEL-SCI Corporation ( CVM), down 17.1% and Senesco Technologies ( SNTI), down 12.7% , were all laggards within the health care sector with Ariad Pharmaceuticals ( ARIA) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Biotech Stock Mailbag: Rebounding From Hillary's Drug Tweet; Global Blood Weighs on Bluebird

The Street Can't Help but Love Amgen

Biotech Stock Bubble Talk Deflated By Cost-Conscious Buyers

Trade-Ideas: Onyx Pharmaceuticals (ONXX) Is Today's "Water-Logged And Getting Wetter" Stock

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan